Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials.

ABSTRACT: The minimum clinically important difference (MCID) is a measure of the minimal clinically relevant change. The MCID represents the smallest difference in score on the measure or domain of interest which patients or clinicians perceive as beneficial or as meaningful decline. The MCID is not an alternative clinical trial outcome; it does not apply to group measures and is used as a means of determining whether an individual patient has reached a threshold of change. MCIDs have been derived for symptomatic treatments and for disease targeted therapies. MCIDs have been derived for nearly all clinical trial instruments used in AD therapeutic research. Application of the MCID to patients on disease-targeted therapies requires awareness of the expected increasing treatment-no treatment difference

SUBMITTER: Cummings J 

PROVIDER: S-EPMC11891559 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature